Literature DB >> 22918997

Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL.

Radha Rajasingham, David R Boulware.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22918997      PMCID： PMC3501329          DOI： 10.1093/cid/cis725

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  7 in total

1.  Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.

Authors:  David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

Review 2.  Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care.

Authors:  Radha Rajasingham; David B Meya; David R Boulware
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-15       Impact factor: 3.731

Review 3.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.

Authors:  Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

4.  Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Jonathan E Kaplan; Constance Benson; King K Holmes; John T Brooks; Alice Pau; Henry Masur
Journal:  MMWR Recomm Rep       Date:  2009-04-10

5.  Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort.

Authors:  Barbara Castelnuovo; Yukari C Manabe; Agnes Kiragga; Moses Kamya; Philippa Easterbrook; Andrew Kambugu
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

6.  Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.

Authors:  Cheryl A Liechty; Peter Solberg; Willy Were; John Paul Ekwaru; Ray L Ransom; Paul J Weidle; Robert Downing; Alex Coutinho; Jonathan Mermin
Journal:  Trop Med Int Health       Date:  2007-08       Impact factor: 2.622

7.  Late HIV testing - 34 states, 1996-2005.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-06-26       Impact factor: 17.586
  7 in total
  15 in total

1.  Serotype sensitivity of a lateral flow immunoassay for cryptococcal antigen.

Authors:  Marcellene A Gates-Hollingsworth; Thomas R Kozel
Journal:  Clin Vaccine Immunol       Date:  2013-01-30

2.  Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.

Authors:  Radha Rajasingham; Rachel M Smith; Benjamin J Park; Joseph N Jarvis; Nelesh P Govender; Tom M Chiller; David W Denning; Angela Loyse; David R Boulware
Journal:  Lancet Infect Dis       Date:  2017-05-05       Impact factor: 25.071

3.  New US Food and Drug Administration Approvals Decrease Generic Flucytosine Costs.

Authors:  Radha Rajasingham; David R Boulware
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

Review 4.  Cryptococcus gattii infections.

Authors:  Sharon C-A Chen; Wieland Meyer; Tania C Sorrell
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 5.  Cryptococcosis.

Authors:  Eileen K Maziarz; John R Perfect
Journal:  Infect Dis Clin North Am       Date:  2016-03       Impact factor: 5.982

6.  Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.

Authors:  Jennie McKenney; Sean Bauman; Brandon Neary; Roger Detels; Audrey French; Joseph Margolick; Brian Doherty; Jeffrey D Klausner
Journal:  Clin Infect Dis       Date:  2014-11-24       Impact factor: 9.079

Review 7.  Asymptomatic cryptococcemia in resource-limited settings.

Authors:  Ana-Claire Meyer; Mark Jacobson
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

Review 8.  Cryptococcal infections: changing epidemiology and implications for therapy.

Authors:  Ricardo M La Hoz; Peter G Pappas
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

9.  Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam.

Authors:  Rachel M Smith; Tuan Anh Nguyen; Hoang Thi Thanh Ha; Pham Hong Thang; Cao Thuy; Truong Xuan Lien; Hien T Bui; Thai Hung Le; Bruce Struminger; Michelle S McConnell; Robyn Neblett Fanfair; Benjamin J Park; Julie R Harris
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

10.  Evaluation of a Cryptococcal Antigen Lateral Flow Assay and Cryptococcal Antigen Positivity at a Large Public Hospital in Atlanta, Georgia.

Authors:  Kristin R V Harrington; Yun F Wang; Paulina A Rebolledo; Zhiyong Liu; Qianting Yang; Russell R Kempker
Journal:  Open Forum Infect Dis       Date:  2021-03-12       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.